Evaluate VRDN stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in VRDN? | Glauxie AI

Q: What are the risks of investing in VRDN?

Viridian Therapeutics, Inc. (VRDN) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Stephen F. Mahoney. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in... Employees: 252.

Q: How much debt does VRDN have?

Review VRDN total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is VRDN a good long-term investment?

Evaluate VRDN as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in VRDN?

🦉

Viridian Therapeutics, Inc. (VRDN)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOStephen F. Mahoney

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody,...

Key Executives

Name	Title
Anthony Casciano	Chief Commercial Officer
Eric N. Olson	Co-Founder & Chairman of Scientific Advisory Board
Jennifer Tousignant	Chief Legal Officer & Corporate Secretary
Marvin H. Caruthers	Co-Founder & Scientific Advisory Board Member
Melissa Manno	Chief Human Resources Officer
Michael R. Bristow	Co-Founder & Member of the Scientific Advisory Board

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

VRDN Profile Financials

Is VRDN stock safe? How much debt does VRDN have? Is VRDN a good long-term investment?